Coverage
-
April 26, 2013
A Washington federal judge unsealed a sharply worded opinion Friday explaining her decision to suspend approval of a generic version of Bayer AG's patented cattle medication Baytril 100, saying the U.S. Food and Drug Administration had presented an "exceptionally weak" argument for allowing a rival product.
2 other articles on this case.
View all »